Is proteinuria reversible, after withdrawal of mammalian target of rapamycin inhibitors?

Transplantation Proceedings

Volumn 43, Issue 6, 2011, Pages 2194-2195

  Arnau, A ^a   Ruiz, J C ^a   Rodrigo, E ^a   Quintanar, J A ^a   Arias, M ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CREATININE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; TACROLIMUS;

ARTICLE; BONE MARROW DISEASE; CHRONIC ALLOGRAFT NEPHROPATHY; DIABETES MELLITUS; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; GRAFT RECIPIENT; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; NEOPLASM; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RESPIRATORY TRACT INFECTION; SKIN DISEASE; WOUND HEALING IMPAIRMENT;

BIOLOGICAL MARKERS; CALCINEURIN; CREATININE; DRUG SUBSTITUTION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PROTEINURIA; RETROSPECTIVE STUDIES; SPAIN; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 80051690332     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.06.045     Document Type: Article

References (3)

1. V. Bumbea, N. Kamar, and D. Ribes Long-term results in renal transplant patients with allograft disfunction after switching from calcineurin inhibitors to sirolimus Nephrol Dial Transplant 20 2005 2517
2. E. Letavernier, and C. Legendre mTOR inhibitors-induced proteinuria: mechanisms, significance and management Transplant Rev (orlando) 22 2008 125
3. F. Diekmann, K. Budde, and F. Oppenheimer Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction Am J Transplant 4 2004 1869